Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase , in patients with advanced cancer.
http://www.businesswire.com/news/topix/20130626005613/en
http://www.businesswire.com/news/topix/20130626005613/en
No comments:
Post a Comment